328 related articles for article (PubMed ID: 24403566)
21. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
22. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
[TBL] [Abstract][Full Text] [Related]
23. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
Gonzalez A; Agarwal-Sinha S
Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
[TBL] [Abstract][Full Text] [Related]
24. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
25. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
26. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
27. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
28. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA; Kuffel RR
Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
[TBL] [Abstract][Full Text] [Related]
31. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
J Ocul Pharmacol Ther; 2011 Dec; 27(6):623-7. PubMed ID: 21823985
[TBL] [Abstract][Full Text] [Related]
33. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.
Honda S; Hirabayashi H; Tsukahara Y; Negi A
Graefes Arch Clin Exp Ophthalmol; 2008 Jul; 246(7):1061-3. PubMed ID: 18320201
[TBL] [Abstract][Full Text] [Related]
34. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
36. Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years.
Hammer JD; Nguyen H; Palmer J; Furtney S; Agarwal-Sinha S
Clin Ther; 2023 Jan; 45(1):4-16. PubMed ID: 36581528
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Vascular Outgrowth Rate and Retinal Vascular Development Border after Intravitreal Injection of Aflibercept or Bevacizumab to Treat Retinopathy of Prematurity.
Vural A; Yıldız Ekinci D
Ophthalmologica; 2020; 243(2):86-93. PubMed ID: 31593948
[TBL] [Abstract][Full Text] [Related]
38. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
39. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.
Sternfeld A; Rahmani S; Rossen JL; Zhang DL; Li YD; Quan VL; Huang R; Yoon HH
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1915-1921. PubMed ID: 34851464
[TBL] [Abstract][Full Text] [Related]
40. Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment.
Bayramoglu SE; Sayin N
Eur J Ophthalmol; 2022 May; 32(3):1430-1440. PubMed ID: 34851169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
